(Q38419117)

English

Follicular lymphoma in Sweden: nationwide improved survival in the rituximab era, particularly in elderly women: a Swedish Lymphoma Registry study

scientific article published on 25 August 2014

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

2 September 2017

Follicular lymphoma in Sweden: nationwide improved survival in the rituximab era, particularly in elderly women: a Swedish Lymphoma Registry study (English)

1 reference

Europe PubMed Central

PubMed publication ID

2 September 2017

0 references

follicular lymphoma

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Björn E Wahlin

11

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25151959%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

author name string

H R Junlén

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25151959%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

S Peterson

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25151959%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

E Kimby

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25151959%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

S Lockmer

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25151959%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

O Lindén

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25151959%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

H Nilsson-Ehle

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25151959%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

M Erlanson

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25151959%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

H Hagberg

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25151959%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

A Rådlund

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25151959%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

O Hagberg

10

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25151959%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

language of work or name

1 reference

based on heuristic

inferred from title

publication date

25 August 2014

1 reference

Europe PubMed Central

PubMed publication ID

2 September 2017

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25151959%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

29

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25151959%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25151959%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

668-676

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25151959%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

https://scigraph.springernature.com/pub.10.1038/leu.2014.251

0 references

How we manage follicular lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.251

21 January 2018

Direct effect of rituximab in B-cell-derived lymphoid neoplasias: mechanism, regulation, and perspectives.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.251

21 January 2018

CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.251

21 January 2018

Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP al

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.251

21 January 2018

Rituximab Added to First-Line Mitoxantrone, Chlorambucil, and Prednisolone Chemotherapy Followed by Interferon Maintenance Prolongs Survival in Patients With Advanced Follicular Lymphoma: An East German Study Group Hematology and Oncology Study

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.251

21 January 2018

Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: results of the GELA-GOELAMS FL2000 study

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.251

21 January 2018

Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.251

21 January 2018

Long-term molecular remissions in patients with indolent lymphoma treated with rituximab as a single agent or in combination with interferon alpha-2a: a randomized phase II study from the Nordic Lymphoma Group

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.251

21 January 2018

New treatment options have changed the survival of patients with follicular lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.251

21 January 2018

Improvements in observed and relative survival in follicular grade 1-2 lymphoma during 4 decades: the Stanford University experience

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.251

21 January 2018

Follicular lymphoma international prognostic index.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.251

21 January 2018

Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.251

21 January 2018

A systematic overview of chemotherapy effects in indolent non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.251

21 January 2018

High-dose therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin's lymphoma: results from the randomized European CUP trial

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.251

21 January 2018

Higher World Health Organization grades of follicular lymphoma correlate with better outcome in two Nordic Lymphoma Group trials of rituximab without chemotherapy

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.251

21 January 2018

Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.251

21 January 2018

Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.251

21 January 2018

The relative survival rate

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.251

21 January 2018

Interpreting trends in cancer patient survival

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.251

21 January 2018

An approach to estimation in relative survival regression.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.251

21 January 2018

Patterns of survival of follicular lymphomas at a single institution through three decades.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.251

21 January 2018

Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.251

21 January 2018

Prognostic factors in diffuse large B-cell lymphoma treated by risk-adopted therapy

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.251

21 January 2018

Prognostic factors in patients with diffuse large B cell lymphoma: Before and after the introduction of rituximab.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.251

21 January 2018

Male gender is an adverse prognostic factor in B-cell lymphoma patients treated with immunochemotherapy.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.251

21 January 2018

Real world data on primary treatment for mantle cell lymphoma: a Nordic Lymphoma Group observational study

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.251

21 January 2018

Prognostic role of gender in diffuse large B-cell lymphoma treated with rituximab containing regimens: a Fondazione Italiana Linfomi/Grupo de Estudos em Moléstias Onco-Hematológicas retrospective study

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.251

21 January 2018

The role of sex and weight on rituximab clearance and serum elimination half-life in elderly patients with DLBCL.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.251

21 January 2018

Suboptimal dosing of rituximab in male and female patients with DLBCL.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.251

21 January 2018

Clinical significance of the WHO grades of follicular lymphoma in a population-based cohort of 505 patients with long follow-up times.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.251

21 January 2018

Rituximab monoclonal antibody as initial systemic therapy for patients with low-grade non-Hodgkin lymphoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/25151959

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

High-dose therapy and autologous stem-cell support for chemosensitive transformed low-grade follicular non-Hodgkin's lymphoma: a case-matched study from the European Bone Marrow Transplant Registry

1 reference

https://pubmed.ncbi.nlm.nih.gov/25151959

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Improvement of overall and failure-free survival in stage IV follicular lymphoma: 25 years of treatment experience at The University of Texas M.D. Anderson Cancer Center

1 reference

https://pubmed.ncbi.nlm.nih.gov/25151959

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Patterns of survival in patients with recurrent follicular lymphoma: a 20-year study from a single center

1 reference

https://pubmed.ncbi.nlm.nih.gov/25151959

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Stage I and II non-Hodgkin's lymphoma. Results of regional radiation therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/25151959

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Rituximab dose-escalation trial in chronic lymphocytic leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/25151959

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/25151959

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation

1 reference

https://pubmed.ncbi.nlm.nih.gov/25151959

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.

1 reference

https://pubmed.ncbi.nlm.nih.gov/25151959

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38419117&oldid=1758514316"